000141691 001__ 141691
000141691 005__ 20240229105129.0
000141691 0247_ $$2doi$$a10.1016/j.urology.2018.06.013
000141691 0247_ $$2pmid$$apmid:29940234
000141691 0247_ $$2ISSN$$a0090-4295
000141691 0247_ $$2ISSN$$a1527-9995
000141691 037__ $$aDKFZ-2018-01962
000141691 041__ $$aeng
000141691 082__ $$a610
000141691 1001_ $$0P:(DE-HGF)0$$aRohrmann, Sabine$$b0$$eFirst author
000141691 245__ $$aLifestyle and Progression of Lower Urinary Tract Symptoms in German Men-Results From the EPIC-Heidelberg Cohort.
000141691 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000141691 3367_ $$2DRIVER$$aarticle
000141691 3367_ $$2DataCite$$aOutput Types/Journal article
000141691 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542957361_24581
000141691 3367_ $$2BibTeX$$aARTICLE
000141691 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141691 3367_ $$00$$2EndNote$$aJournal Article
000141691 520__ $$aTo examine if lower urinary tract symptom (LUTS) progression was related to anthropometric and lifestyle factors.The analysis included 5495 men who participated in the EPIC-Heidelberg cohort (recruited 1994-1998) and who reported an International Prostate Symptom Score < 8 at follow-up 4 (FUP4, 2007-2009), had not reported taking α-adrenoreceptor antagonists or 5-α reductase inhibitors or prostate surgery for benign prostatic hyperplasia/LUTS treatment. LUTS progression was defined as an International Prostate Symptom Score ≥ 8 at FUP5 (2010-2012). Using logistic regression analysis, education, marital status, satisfaction with life, satisfaction with health, history of diabetes and of hypertension, smoking, alcohol consumption, body mass index (BMI), waist circumference, and physical activity were examined as potential LUTS risk factors adjusting for age.Increase in BMI between baseline and FUP4 of ≥ 2 BMI units was related to LUTS progression (odds ratio 1.30, 95% confidence interval 1.08-1.57) compared with stable BMI. Compared to men who were very satisfied with life at baseline, those who were satisfied (1.28, 1.11-1.47), unsatisfied (1.80, 1.31-2.46) or very unsatisfied with life (1.43, 0.62-3.34) were more likely to report LUTS progression. Men with longer education had higher odds of LUTS progression than men with primary education only (1.25, 1.06-1.48). Adjusting for BMI or lifestyle factors did not attenuate these associations. Smoking habits, alcohol consumption, physical activity, self-reported history of diabetes or hypertension, and marital status were not related with LUTS progression.Our results confirm some, but not all previously observed risk factors for LUTS progression.
000141691 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141691 588__ $$aDataset connected to CrossRef, PubMed,
000141691 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b1$$udkfz
000141691 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b2$$eLast author$$udkfz
000141691 773__ $$0PERI:(DE-600)2011025-X$$a10.1016/j.urology.2018.06.013$$gVol. 120, p. 192 - 196$$p192 - 196$$tUrology$$v120$$x0090-4295$$y2018
000141691 909CO $$ooai:inrepo02.dkfz.de:141691$$pVDB
000141691 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141691 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141691 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141691 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141691 9141_ $$y2018
000141691 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141691 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bUROLOGY : 2017
000141691 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141691 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141691 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141691 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141691 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141691 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141691 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141691 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141691 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141691 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141691 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141691 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141691 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141691 980__ $$ajournal
000141691 980__ $$aVDB
000141691 980__ $$aI:(DE-He78)C020-20160331
000141691 980__ $$aUNRESTRICTED